logo-loader
viewHumanigen, Inc.

Humanigen eyes evaluating lenzilumab in treating lung damage caused by coronavirus

It cited a recent study that looked at samples from patients with severe pneumonia resulting from the virus

Humanigen, Inc. - Humanigen to evaluate lenzilumab in treating lung damage caused by coronavirus
Humanigen 'is positioned to evaluate lenzilumab's potential role as part of a response to the coronavirus crisis,' said CEO Dr Cameron Durrant

Humanigen Inc (OTCMKTS:HGEN) announced Monday that it is exploring clinical-stage strategies and partnerships to evaluate whether lenzilumab may reduce or prevent cytokine storm resulting from the coronavirus infection (COVID-19). 

A recent pre-publication titled "Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus," supports the hypothesis that cytokine storm-induced immune mechanism have contributed to patient mortality with the current pandemic strain of coronavirus, according to a statement. 

The severe clinical features associated with COVID-19 and other coronaviruses result from an inflammation-induced lung injury requiring intensive care unit (ICU) care and mechanical ventilation. This lung injury is a result of cytokine storm resulting from a hyper-reactive immune response. The lung injury that leads to death is not directly related to the virus but appears to be a result of a hyper-reactive immune response to the virus triggering a cytokine storm that can continue even after viral titers begin to fall. 

READ: Humanigen appoints Korn Ferry senior exec Cheryl Buxton to board

The authors of the study assessed samples from patients with severe pneumonia resulting from COVID-19 infection to identify whether inflammatory factors such as GM-CSF, IL-6, IFN-gamma and TNF-alpha were implicated.

The authors noted that steroid treatment in such cases has been disappointing in terms of outcome, but suggest that a monoclonal antibody that targets GM-CSF may prevent or curb the hyperactive immune response caused by COVID-19. 

Humanigen said it believes that the authors' findings are clearly worthy of further investigation, suggesting that to reduce or eradicate ICU care and prevent deaths from COVID-19 infection, an intervention may be needed to prevent cytokine storm.

Lenzilumab has been shown to prevent cytokine storm in animal models and this work has been published in peer-reviewed publications. Patients are soon expected to be enrolled in a clinical study to determine lenzilumab's effect on cytokine storm associated with the hyperactive immune response associated with CAR-T therapy in collaboration with Kite Pharma.

"These data confirm previously published data from the SARS and the MERS outbreaks, caused by strains of coronavirus different from the current COVID-19 strains, which indicated that severe pneumonia in SARS and MERS resulted from cytokine storm,” said CEO Dr Cameron Durrant.

“These new data also suggest that GM-CS F may be a critical triggering cytokine in the increased mortality in the current coronavirus pandemic. Humanigen has pioneered the field of GM-CSF neutralization and published data related to lenzilumab neutralization of GM-CSF and amelioration of cytokine storm in animal models. We have also completed two Phase I and two Phase II studies with lenzilumab, including in patients with severe respiratory impairment where lenzilumab demonstrated benefit."

Durrant continued: "We expect to commence patient enrollment in the joint Kite Pharma/Humanigen ZUMA-19 study to examine the impact of lenzilumab to reduce cytokine storm, amongst other measures, in the context of CAR-T. With our extensive intellectual property in GM-CSF neutralization, Humanigen is positioned to evaluate lenzilumab's potential role as part of a response to the coronavirus crisis and is actively exploring clinical-stage strategies and partnerships in this regard."

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Humanigen, Inc.

Price: 0.94 USD

OTCMKTS:HGEN
Market: OTCQB
Market Cap: $118.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen achieves significant milestone in dosing first coronavirus patient...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive its first coronavirus patient has been dosed in a Phase 3 trial of its drug lenzilumab. Durrant says the now ongoing trial is the first randomized, double-blind, placebo-controlled, multi-center, Phase 3 study of an anti-GM-CSF...

2 weeks ago

3 min read